Recuro Proud to Support 2021 SIIA Annual Meeting: Recuro CEO Michael Gorton Participates on Visionary Panel Exploring Future of Digital Health   

SIIA’s 41st Annual National Educational Conference, October 3-5, 2021, Austin, TX was a great opportunity for Recuro Health to support SIIA and for Recuro’s rollout to employers of its multi-prong digital health solution, including COVID-19 antigen testing and vaccine tracking status capabilities. 

On a voluntary basis to all attendees, Recuro provided rapid COVID-19 antigen tests and a component to track testing status. A complementary program was also introduced that suppo

rts vaccine tracking status and images of the vaccine card which are tied to a management portal, making this a robust tool of great value to employers and employees.

Recuro’s COVID-19 rapid testing solution has generated wide receptivity among the nation’s employers, including federal and state governments and corporate healthcare decision-makers. In fact, Recuro was among 12 technology companies selected by the U.S. Department of Health and Human Services (HHS) and recognized for developing digital solutions to ensure that COVID-19 diagnostic testing data is efficiently, securely and accurately transmitted to key stakeholders, including federal, state, local and tribal governments, patients, providers, employers, schools, consumers and others.

 The need of expanded COVID testing is more than simply acquiring tests. Recuro’s optimal solution leverages eligibility information and supports onboarding, scheduling, test distribution, validation of results and aggregate reporting. This scalable solution embodies a structured, integrated, end-to-end process that delivers more than just bulk testing supplies. 

Not All COVID-19 Testing Strategies are the Same 

While there are many strategies for COVID-testing available to employers, not all solutions are the same. 

Recuro launched one of the first comprehensive employer testing platforms for COVID-19, supporting employers with key decision-making and OSHA requirements for employees’ safe return-to-work.  

As best-of-breed solution, the Recuro COVID-19 testing solution is safe, customizable and compliant. It also readily integrates within an organization’s broader health and wellness strategy, is positioned to work with any primary physician and features a simple design that is accessible and easy to use. These attributes ensure safe workplaces as the various variants rages across the U.S. 

Understanding the Delta and Other Variants 

Meanwhile, the need of expanded COVID testing is undeniable. In addition, the Centers for Disease Control and Prevention (CDC) recently reported that there is a variant classification designated Variants Being Monitored (VBM) 

As of September 21, 2021, the following variants are classified as VBM:  

  •  Alpha (B.1.1.7, Q.1-Q.8)  
  •  Beta (B.1.351, B.1.351.2, B.1.351.3)  
  •  Gamma (P.1, P.1.1, P.1.2)  
  •  Epsilon (B.1.427, B.1.429)  
  •  Eta (B.1.525)  
  •  Iota (B.1.526)  
  •  Kappa (B.1.617.1)  
  •  B.1.617.3  
  •  Mu (B.1.621, B.1.621.1)  
  •  Zeta (P.2)  

CEO Michael Gorton Shares Insights about Digital Health 

Recuro Health is part of the digital health industry that is transforming patient care. This strong emphasis on digital health’s potential is causing a shift in healthcare like never before and providing countless opportunities for employers, providers and payers. 

Digital health has added to the care delivery system to improve access, quality and affordability along with patient outcome. As digital health investment  shatters records, SIIA’s annual meeting hosted a panel of digital health visionaries Oct. 4, featuring, Michael Gorton, CEO of Recuro Health.  

Gorton joined healthcare leaders on a live panel presentation “Transforming Employee Health Care Experience Through Digital Health Advancements (LIVE).” Attendees learned about digital strategies, including telehealth and remote patient monitoring, as panelists shared their perspectives on how digital solutions impact chronic care management, the importance of digital solutions for medication adherence and compliance and how employers can support telehealth use among employees. 

Gorton was joined by panelists Dea Belazi, president and CEO, AscellaHealth; Jeff Dobro, M.D., FACR, chief innovation officer, Transcarent; and Chris Michalak, CEO, Virgin Pulse. 

Finding the Optimal Digital Health Solution 

 The optimal digital health solution can scale and support the traditional healthcare delivery system by advancing integrated care, risk stratification and diagnostics and bringing to reality improved outcomes and more efficient care. 

The best digital health solution is part of an integrated patient-centered digital medical home strategy like Recuro’s that securely manages the appropriate providers visits, capturing and aggregating the relevant diagnostic information and much more.  

The best solution needs to be fully customizable and tailored to meet the needs of a certain population, allowing patients to engage with physicians, receive more personalized care and monitor their own health, no matter their location or circumstance. It also provides tools, resources and support to manage a host of health conditions.  

For more information about Recuro’s capabilities, contact info@recurohealth.com  

default-image2

Recuro Health Supports SIIA Annual Meeting: Provides Voluntary COVID-19 Antigen Rapid Testing for Attendees: CEO Michael Gorton Panel Presenter

Recuro Health is proud to support the SIIA annual conference by providing COVID-19 antigen rapid tests on a voluntary basis to all attendees during the...